Glenmark Consumer Care sales rise 28% as Candid and Scalpe grow over 30%
Glenmark Pharmaceuticals reported Q1 FY27 consumer-care primary sales of ₹155.8 crore, up 28% year-on-year, led by over-30% growth in Candid and Scalpe. India formulation sales rose 15.5% to ₹1,432.1 crore.
Glenmark’s Q1 FY27 profit rose 930% to ₹483 crore as India formulation sales grew 15.5% and consumer-care sales climbed 28%. Flagship Candid and Scalpe grew over 30%, while North America revenue increased 41.1%.
Why this matters
With no prior related signals listed, Glenmark’s Q1 FY27 update establishes a sales-growth baseline: consumer care rose 28%, while Candid and Scalpe each grew more than 30%.
Retail-company signals are accelerating, up 217650% quarter on quarter.